Cyclo-RGDfK - Integrin 抑制劑 - 生命科學試劑 - MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemECyclo(-RGDfK)Cat. No.: HY-P0023CAS No.: 161552-03-0分式: CHNO分量: 603.67Sequence: Cyclo(Arg-Gly-Asp-Phe-Lys)Sequence Shortening:Cyclo(RGDFK)作靶點: Integrin作通路: Cytoskeleton儲存式: Powder -80C 2 years-20C 1 yearIn solvent -80C 6 months-2

2、0C 1 month溶解性數(shù)據(jù)體外實驗 DMSO : 125 mg/mL (207.07 mM; Need ultrasonic)H2O : 50 mg/mL (82.83 mM; Need ultrasonic)Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 1.6565 mL 8.2827 mL 16.5653 mL5 mM 0.3313 mL 1.6565 mL 3.3131 mL10 mM 0.1657 mL 0.8283 mL 1.6565 mL請根據(jù)產品在不同溶劑中的溶解度，選擇合適的溶劑配制儲備液，并請注意儲備液的保存式和期限

3、。體內實驗請根據(jù)您的實驗動物和給藥式選擇適當?shù)娜芙獍?，配制前請先配制澄的儲備液，再依次添加助溶?為保證實驗結果的可靠性，體內實驗的作液，建議您現(xiàn)現(xiàn)配，當天使；澄的儲備液可以根據(jù)儲存條件，適當保存；以下溶劑前的百分 指該溶劑在您配制終溶液中的體積占)：1. 請依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.08 mg/mL (3.45 mM); Clear solution1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemE2. 請依序添加每種溶劑： 10% DMS

4、O 90% (20% SBE-CD in saline)Solubility: 2.08 mg/mL (3.45 mM); Clear solution3. 請依序添加每種溶劑： 10% DMSO 90% corn oilSolubility: 2.08 mg/mL (3.45 mM); Clear solutionBIOLOGICAL ACTIVITY物活性 Cyclo(-RGDfK)有效，選擇性的整合素 v3 抑制劑，其 IC50 值為 0.94 nM。IC50 & Target IC50: 0.94 nM (v3 integrin) 1.體外研究 Cyclo(-RGDfK) is a p

5、otent and selective inhibitor of the v3 integrin, with a IC50 of 0.94 nM 1.(66)GaDOTA-E-c(RGDfK)2 can be prepared with high radiochemical purity (97%), specific activity (36-67GBq/M), in vitro stability, and moderate protein binding. MicroPET imaging up to 24 post-injection showedcontrasting tumors

6、reflecting v3-targeted tracer accumulation 2.戶使本產品發(fā)表的科研獻 ACS Appl Mater Interfaces. 2019 Jul 31;11(30):26648-26663.See more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Simecek J, et al. Benefits of NOPO as chelator in gallium-68 peptides, exemplified by preclinical characterization

7、of (68)Ga-NOPO-c(RGDfK). Mol Pharm. 2014 May 5;11(5):1687-95.2. Lopez-Rodriguez V, et al. Preparation and preclinical evaluation of (66)Ga-DOTA-E(c(RGDfK)2 as a potential theranosticradiopharmaceutical. Nucl Med Biol. 2015 Feb;42(2):109-14.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use